Skip to main content

Advertisement

SpringerLink
Log in

The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice

  • Review
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003; (362 9386):755–757.

  2. Lopez-Sendon J, Swedberg K, McMurray, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25(16):1454–1470.

    Article  PubMed  Google Scholar 

  3. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058–2068.

    Article  CAS  PubMed  Google Scholar 

  4. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction–May they rest in PEACE? N Engl J Med 2004;351(20):2115–2117.

    Article  CAS  PubMed  Google Scholar 

  5. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058–2068.

    Article  CAS  PubMed  Google Scholar 

  6. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998;18(9):1433–1439.

    CAS  PubMed  Google Scholar 

  7. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(9A):1L–20L.

    Article  CAS  PubMed  Google Scholar 

  8. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95(2):473–478.

    CAS  PubMed  Google Scholar 

  9. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100(21):2131–2134.

    CAS  PubMed  Google Scholar 

  10. van der Harst P, Wagenaar LJ, Buikema H, et al. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol 2005; in press.

  11. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–677.

    Article  CAS  PubMed  Google Scholar 

  12. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342(8875):821–828.

    Google Scholar 

  13. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670–1676.

    Article  CAS  PubMed  Google Scholar 

  14. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355(9215):1575–1581.

    Article  CAS  PubMed  Google Scholar 

  15. Pitt B, O’Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87(9):1058–1063.

    Article  CAS  PubMed  Google Scholar 

  16. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group [comment]. Circulation 1992;86:100–110.

    Google Scholar 

  17. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995;25(2):362–369.

    Article  CAS  PubMed  Google Scholar 

  18. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001;87(5):542–546.

    Article  CAS  PubMed  Google Scholar 

  19. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000;35(4):881–888.

    Article  CAS  PubMed  Google Scholar 

  20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145–153.

    Article  CAS  PubMed  Google Scholar 

  21. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782–788.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University Medical Center, Groningen, The Netherlands

    Adriaan A. Voors, Dirk J. van Veldhuisen & Wiek H. van Gilst

  2. Department of Clinical Pharmacology, University Medical Center, Groningen, The Netherlands

    Wiek H. van Gilst

  3. Department of Cardiology, University Medical Center, Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands

    Adriaan A. Voors

Authors
  1. Adriaan A. Voors
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk J. van Veldhuisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wiek H. van Gilst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adriaan A. Voors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voors, A., van Veldhuisen, D. & van Gilst, W. The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice. Cardiovasc Drugs Ther 20, 69–73 (2006). https://doi.org/10.1007/s10557-006-6570-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-006-6570-1

Key Words

Search

Navigation